Novel Crystalline Forms Of Fexofenadine Hydrochloride And Process Of

Novel Crystalline Forms Of Fexofenadine Hydrochloride And Process Of Preparing The Same

Abstract: NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-l- PIPERIDINYL]-l-HYDROXYBUTYL]-A,A-DIMETHYLBENZENEACETIC ACID HYDROCHLORIDE AND PROCESS OF PRODUCING THE SAME Abstract of the Invention Disclosed herein are novel crystalline forms of 4-[4-[4-(Hydroxydiphenylmethyl)-l-piperidinyl]-1 -hydroxybutyl]-a, a-dimethylbenzeneacetic acid hydrochloride designated as Form M1 and M11 and process for producing the same thereof.

Patent Information

Application #

Filing Date

01 February 2008

Publication Number

22/2010

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

MATRIX LABORATORIES LIMITED

1-1-151/1, 4TH FLOOR, SAI RAM TOWERS, ALEXANDER ROAD, SECUNDERABAD-500 003 ANDHRA PRADESH, INDIA

Inventors

1. JETTI, RAMAKOTESHWARA, RAO

C/O MATRIX LABORATORIES LIMITED, PLOT NO.34A, ANRICH INDUSTRIAL ESTATE, BOLLARAM, JINNARAM MANDAL-502 325, MEDAK DIST. ANDHRA PRADESH, INDIA

2. RAVAL, CHETAN, KANAIYALAL

C/O MATRIX LABORATORIES LIMITED, PLOT NO.34A, ANRICH INDUSTRIAL ESTATE, BOLLARAM, JINNARAM MANDAL-502 325, MEDAK DIST. ANDHRA PRADESH, INDIA

3. TYAGI, OM DUTT

C/O MATRIX LABORATORIES LIMITED, PLOT NO.34A, ANRICH INDUSTRIAL ESTATE, BOLLARAM, JINNARAM MANDAL-502 325, MEDAK DIST. ANDHRA PRADESH, INDIA

Specification

FIELD OF THE INVENTION This invention, in general relates to novel crystalline forms of 4-[4-[4-(Hydroxydiphenylmethyl)-l-piperidinyl]-l-hydroxybutyl]-a,a-dimethylbenzeneacetic acid hydrochloride (fexofenadine). More particularly, the invention relates to novel crystalline forms Form M1 and Form M11 and process for producing the same thereof. BACKGROUND OF THE INVENTION 4-[4-[4-(Hydroxydiphenylmethyl)-1 -piperidinyl]-1 -hydroxybutyl]-a,a-dimethylbenzeneacetic acid of Formula (I) (Fexofenadine) is an H1 receptor antagonist and a useful antihistaminic drug. It has low permeability into central nervous system tissues and weak antimuscarinic activity, causing it to have fewer systemic side effects. US 4,254,129, discloses the antihistaminic activity of fexofenadine and process for preparing the same thereof. The fexofenadine is produced by reacting ethyl

Documents

Application Documents

#	Name	Date
1	273-CHE-2008 FORM-1 26-03-2008.pdf	2008-03-26
2	273-CHE-2008 CORREPONDENCE OTHERS 26-03-2008.pdf	2008-03-26
3	273-CHE-2008 FORM-18 19-05-2008.pdf	2008-05-19
4	273-CHE-2008 POWER OF ATTORNEY 09-07-2008.pdf	2008-07-09
5	273-CHE-2008 CORREPONDENCE OTHERS 09-07-2008.pdf	2008-07-09
6	273-CHE-2008 FORM-3 30-01-2009.pdf	2009-01-30
7	273-CHE-2008 FORM-2 30-01-2009.pdf	2009-01-30
8	273-CHE-2008 DRAWINGS 30-01-2009.pdf	2009-01-30
9	273-CHE-2008 DESCRIPTION(COMPLETE) 30-01-2009.pdf	2009-01-30
10	273-CHE-2008 CORREPONDENCE OTHERS 30-01-2009.pdf	2009-01-30
11	273-CHE-2008 FORM-18 19-11-2010.pdf	2010-11-19
12	273-che-2008-form-5.pdf	2011-09-02
13	273-che-2008-form-1.pdf	2011-09-02
14	273-che-2008-form 5.pdf	2011-09-02
15	273-che-2008-form 3.pdf	2011-09-02
16	273-che-2008-form 1.pdf	2011-09-02
17	273-che-2008-description(provisional).pdf	2011-09-02
18	273-che-2008-correspondnece-others.pdf	2011-09-02
19	273-che-2008-claims.pdf	2011-09-02
20	273-che-2008-abstract.pdf	2011-09-02
21	273-CHE-2008 DRAWINGS.pdf	2012-02-23
22	273-CHE-2008 FORM-13 04-09-2013.pdf	2013-09-04
23	Form 13.pdf	2013-09-17
24	Attested copy of Certificate.pdf	2013-09-17
25	Amended Forms.pdf	2013-09-17
26	273-CHE-2008-FER.pdf	2016-11-25
27	Other Document [25-01-2017(online)].pdf	2017-01-25
28	Form 13 [25-01-2017(online)].pdf	2017-01-25
29	273-CHE-2008-AbandonedLetter.pdf	2017-07-13

Search Strategy

1	273del2008_03-11-2016.pdf